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Abstract 
Background: Stratified medicine aims to improve clinical and cost-effectiveness by 
identifying moderators of treatment that indicate differential response to treatment. Cognitive 
Behavioural Therapy (CBT) is often offered as a ‘next-step’ for patients who have not 
responded to antidepressants, but no research has examined moderators of response to CBT 
in this population. We aimed, therefore, to identify moderators of response to CBT in 
treatment resistant depression. 
Methods: We used linear regression to test for interactions between treatment effect and 14 
putative moderator variables using data from the CoBalT randomised controlled trial. This 
trial examined the effectiveness of CBT given in addition to usual care (n = 234) compared 
with usual care alone (n = 235) for primary care patients with treatment resistant depression.  
Results: Age was the only variable with evidence for effect modification (p value for 
interaction term = 0.012), with older patients benefiting the most from CBT. We found no 
evidence of effect modification by any other demographic, life, illness, personality trait, or 
cognitive variable (p ≥ 0.2).  
Conclusions: Given the largely null findings, a stratified approach that might limit offering 
CBT is premature; CBT should be offered to all individuals where antidepressant medication 
has failed. 
Keywords: Depression, cognitive behavioural therapy, CBT, treatment resistance, 
moderators, stratified medicine, primary care.  
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Moderators of treatment response to cognitive behavioural therapy as an adjunct to 
pharmacotherapy for treatment resistant depression in primary care 
Introduction 
Depression is a major contributor to the global burden of disease and projected to be a 
leading cause of disability worldwide by 2030 (Mathers and Loncar, 2006).  There is good 
evidence that cognitive behavioural therapy (CBT) is an effective treatment in previously 
untreated episodes of depression (Butler et al., 2006; Cuijpers et al., 2008). Patients vary 
considerably in their response to CBT with sizable proportions responding either not at all or 
only partially. It is therefore clinically useful to identify which patients will respond. Reliable 
evidence informing this issue remains elusive, however, and clinicians often decide which 
patients to refer to which treatment based on clinical judgements about patient suitability 
(Safran, 1990). In line with the current drive towards stratified medicine that aims to target 
interventions at subgroups of patients who are likely to respond (Hingorani et al., 2013), 
research is needed to identify reliable moderators or effect modifiers of treatment response.   
It is important to distinguish between predictors and moderators. Predictors are prognostic 
factors associated with disease outcomes irrespective of treatment, whereas moderators are 
associated with differential response to treatments (predictors and moderators are assessed at 
baseline and are different from mediators that are on the causal pathway (Kraemer et al., 
2002)). In other words, a moderator will lead to a smaller or larger difference between active 
and comparator groups. Understanding of potential moderators is clinically useful, as this 
would enable clinicians to base treatment choices on the individual’s likelihood of benefiting 
from a given treatment.  A variable is established as a moderator by investigating interactions 
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between that variable and two or more treatment options, ideally within the context of a 
randomised controlled trial (Brookes et al., 2001). Studies designed specifically to test for 
interactions are large, expensive, and therefore rare. Using existing data from good quality 
and well-controlled clinical trials is an efficient and cost-effective alternative, although with 
the potential for lower statistical power (Button et al., 2012).  
Previous studies reporting moderators of response to CBT in controlled trials of adults have 
used small sample sizes, randomising fewer than 63 patients per CBT arm (Elkin et al., 1995; 
Farabaugh et al., 2012; Fournier et al., 2009; Leykin et al., 2007; Sotsky et al., 1991), or have 
compared CBT to antidepressant treatment (Fournier et al., 2009; Leykin et al., 2007).  With 
such small sample sizes these studies were almost certainly underpowered (Brookes et al., 
2001), and whilst understanding which of two treatment options is likely to produce the best 
outcomes is important, in practice, antidepressants and CBT are often prescribed together 
(Button et al., 2012). There is growing evidence that CBT and antidepressants combined are 
more effective than either treatment alone (Cuijpers, 2014; Cuijpers et al., 2009b), and that 
CBT is effective as an adjunct to antidepressants where such  medication has failed (Wiles et 
al., 2013).  Moreover, despite guidance in the UK suggesting CBT be offered to all 
moderately depressed patients, anecdote suggests that in practice CBT is often reserved for 
those patients who have not responded to antidepressant medication. We have previously 
examined moderators of response to CBT delivered by a therapist via the internet as an 
adjunct to usual care that included the option of antidepressants where prescribed (Button et 
al., 2012). However, no previous research has examined moderators of response to CBT as a 
‘next-step’ treatment for primary care patients who have not responded to antidepressants.  
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Few previous studies have examined demographic variables as potential moderators of 
response to CBT in adults using appropriate tests for interaction (Button et al., 2012; Fournier 
et al., 2009; Sotsky et al., 1991). Fournier and colleagues found that being married, 
unemployed, and having more antecedent life events were associated with better response to 
CBT than antidepressants (Fournier et al., 2009). In our previous study, we found that being 
separated/widowed/divorced and having fewer recent stressful life events were associated 
with better responses to CBT compared with a waiting list control (Button et al., 2012). Pre-
treatment severity of depression is the most reliable moderator of response to CBT in the 
literature, with the more severely depressed benefiting most. (Button et al., 2012; Driessen et 
al., 2010; Kiosses et al., 2011; Thompson et al., 2001) There is no previous evidence that 
history or chronicity of depression are moderators of CBT response (Button et al., 2012; 
Fournier et al., 2009), and the evidence for co-morbidity as a moderator  is mixed (Asarnow 
et al., 2009; Farabaugh et al., 2012). Assessing individuals’ suitability for therapy is an 
important part of clinical practice, which often focuses on interpersonal skills, personality, 
and psychological mindedness (Safran, 1990). Personality disorder has been studied in this 
context, with a meta-analysis of well-designed RCTs finding no evidence of moderation on 
response to treatments for depression (Kool et al., 2005). There is, however, some evidence 
that personality traits and dysfunctional attitudes moderate response to CBT relative to 
pharmacotherapy, with more neurotic individuals and individuals with high dysfunctional 
attitudes more likely to respond to antidepressants than to CBT (Bagby et al., 2008; 
Shankman et al., 2013).      
Therefore, the aim of the present study was to examine potential moderators of response to 
CBT given as an adjunct to usual care that included pharmacotherapy as a ‘next step’ 
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treatment for patients whose depression had not responded to treatment with antidepressants 
using data from the CoBalT trial (Wiles et al., 2013). Evidence of moderators in this group 
will inform decisions concerning which patients unresponsive to medication should be 
referred for CBT. We therefore examined the modifying effects of demographic, life events, 
illness, co-morbidity, personality traits and cognitive variables.  
Methods 
Participants 
This study is a secondary analysis of data collected as part of the CoBalT randomised 
controlled trial examining the effectiveness of cognitive behavioural therapy as an adjunct to 
usual care (that included pharmacotherapy) for patients with treatment-resistant depression in 
primary care (Wiles et al., 2013). Definitions of treatment-resistant depression range from 
non-response to at least 4 weeks treatment with antidepressants (WPA, 1974) to more 
stringent definitions such as non-response to multiple courses of treatment (Amsterdam and 
HornigRohan, 1996; Fava, 2003; Fekadu et al., 2009; Thase and Rush, 1997), but there is no 
universally agreed definition. The CoBalT team therefore chose to operationalise this for the 
trial in a way that was applicable to UK primary care and reflects the uncertainty about how 
best to manage depression following non-response to the first line treatment. 
Individuals were eligible for the trial if they were aged between 18-75 years, were currently 
taking antidepressant medication and had been doing so at an adequate dose for at least 6 
weeks, scored 14 or more on the Beck Depression Inventory (BDI-II)(Beck et al., 1996) and 
met the ICD-10 criteria for depression (assessed using the Clinical Interview Schedule – 
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Revised form, CIS-R (Lewis, 1994; Lewis et al., 1992)). A BDI score of 14 or more indicates 
a clinical level of depression, with 14-19 considered mild, 20-28 moderate, and ≥29 severe 
depression. Four hundred and sixty-nine participants were randomised to one of two groups: 
(1) usual care (n = 235) or (2) CBT in addition to usual care (n = 234), which comprised a 
maximum of 18 sessions, each lasting 50-60 minutes, with a CBT therapist. Therapists used 
the CBT for depression treatment manuals (Beck et al., 1979; Beck, 1995; Moore and 
Garland, 2003). Treatment allocation was stratified by recruitment centre and minimised, 
with a probability weighting of 0.8 (Brown et al., 2005), according to the following variables: 
baseline BDI-II score (mild, moderate, severe); whether participant’s general practice had a 
counsellor (yes/no); prior treatment with antidepressants (yes/no) and duration of their 
current episode of depression (<1 year; 1-2 years; ≥2 years). Minimisation was used in order 
to achieve balance in these important (design) variables across the treatment arms.  
Participants were followed up for a year at intervals of three months, with the BDI-II being 
completed at baseline, six and twelve months. A total of 422 (90%) of participants were 
followed up at 6 months and 396 (84%) at 12 months.    
Outcome 
The outcome variable used in the current study was BDI-II score treated as a continuous 
variable at 6 and 12 months, analysed as a repeated measure to increase power;  427 (91%) of 
patients provided data for at least one follow up. We treated BDI-II score as a continuous 
variable in this exploratory study to retain maximum power and ensure comparability of 
findings with previous studies of effect modification (Button et al., 2012; Fournier et al., 
2009). This is in contrast to the main trial paper, where the primary outcome was a binary 
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variable representing a reduction in BDI-II score of at least 50% compared to baseline (Wiles 
et al., 2013). 
Potential Moderators 
We investigated all variables measured prior to randomisation as potential moderators where 
there was precedent in the literature. The potential moderators were identified from previous 
research and grouped into three general classes: (1) demographic and life factors; (2) illness 
characteristics; and (3) personality, cognition and psychological mindedness. We did not 
investigate patient expectation of outcome or degree of treatment resistance (defined on the 
basis of duration of present symptoms and past treatment with antidepressant drugs), as these 
subgroup analyses are reported in the main trial analysis and indicated no evidence that either 
variable moderated response to CBT (Wiles et al., 2013). All data on potential moderators 
were collected prior to randomisation. 
 
Demographic and life factors 
Age was measured as continuous and categorised into the following groups: (1) <30, (2) 30-
39, (3) 40-49 and (4) >49 years for analysis. Level of education was defined as highest 
educational qualification and categorised as: (1) A level/Higher grade or above, (2) Other 
qualifications – GCSE or equivalent and (3) No formal qualifications. A-levels are UK 
national qualifications generally taken at age 18 years, and qualifications at this level are 
usually required for entry to university or higher education. A-Levels / Higher grade would 
correspond to 12th Grade in the US Education system.  GCSEs are also UK national 
qualifications generally taken at age 16 years, and mark the end of compulsory education in 
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the UK. The age at which GSCEs are taken corresponds to 10th Grade in the US system. For 
marital status the participant selected from the following options: single; separated; divorced; 
widowed; married/living as married, and for the analysis we categorised marital status as: (1) 
Single, (2) Married/Living as married and (3) Separated/widowed/divorced. Eight questions 
selected from the Social and Readjustment Rating Scale (Holmes and Rahe, 1967), dealing 
with bereavement, separation or divorce, serious illness or injury, victim of crime, problems 
with the police resulting in a court appearance, debt, disputes with 
friends/relatives/neighbours and redundancy within the 6 months prior to randomisation were 
used to measure adverse life events. The number of life events were summed and categorised 
as: (1) 0 events, (2) 1-2 events and (3) 3 or more events. 
Illness characteristics 
Two measures of pre-treatment depression severity were used: (i) baseline BDI-II score 
measured as continuous but dichotomized for analysis, for consistency with previous research 
(Button et al., 2012), as (1) Severe (BDI-II score > 28) and (2) Less severe (BDI-II score < 
29); (ii) baseline CIS-R depression severity as a continuous variable, generated by summing 
the depression, depressive ideas, fatigue, concentration, and sleep sections of the CIS-R to 
produce a score ranging from 0 to 21. The BDI-II is not a diagnostic scale, but instead 
provides a measure of depressive symptom severity. The CIS-R, by contrast, provides 
diagnoses in line with ICD-10. We include both to provide insight into the robustness of any 
observed effects. The BDI-II has good psychometric properties (Beck et al., 1988), with an 
internal consistency 0.9 (Wang and Gorenstein, 2013). History of depression was assessed as 
part of the CoBalT baseline questionnaire, in terms of self-reported number of previous 
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episodes of depression and the duration of the current episode. Number of prior episodes of 
depression was categorised as collected: (1) 0-1 episodes, (2) 2-4 episodes and (3) ≥5 
episodes. The duration of the current episode of depression was assessed as a categorical 
variable as: (1) less than 1 year, (2) 1-2 years and (3) more than 2 years. Anxiety was 
measured as the score of the CIS-R anxiety section, range 0-4, with higher score indicating 
more symptoms. Post-traumatic stress disorder was scored as an additive count of symptoms 
on the Primary Care PTSD Screen (PC-PTSD) with a possible range of 0-4 (Prins et al., 
2003) with higher score indicating more symptoms. Longstanding illness was investigated by 
recording participants’ other self-reported illnesses as a categorical variable: (1) No chronic 
illness, (2) Diabetes, (3) Asthma, (4) Arthritis, (5) Heart disease, (6) High blood pressure, (7) 
Lung disease, (8) more than one of the above and (9) none of the above but other.  
Personality, cognition and psychological mindedness 
Dysfunctional attitudes and meta-cognitive awareness were measured as continuous variables 
by summing participants’ responses to the Dysfunctional Attitudes Scale – Short Form, DAS-
SF2 (Beevers et al., 2007) and Meta-cognitive Awareness Questionnaire, MAQ (Teasdale et 
al., 2001) respectively. Neuroticism was measured using the neuroticism subscale of the “Big 
Five” Inventory, BFI (John et al., 1991) and examined as a continuous variable as the mean 
score of the eight test items. Higher score indicates increased neuroticism. The DAS-SF2, 
MAQ, and neuroticism subscale all show good internal consistency, at 0.8 (Beevers et al., 
2007), 0.7 (Teasdale et al., 2001) and 0.8 (Bech et al., 2012) respectively. 
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Statistical analysis   
Treatment effect is defined as the difference in mean BDI-II outcome scores (as a continuous 
variable) between the usual care and intervention arms, adjusted for stratification and 
minimisation (i.e., design) variables. Separate random effects regression models (RRM) were 
carried out for each potential moderator including an interaction term between the relevant 
moderator and treatment allocation, adjusting for the stratification and minimisation (design) 
variables (listed earlier) and time, to test for effect modification on the outcome over 12 
months. Further models, containing a three way interaction (moderator by treatment 
allocation by time) were carried out to investigate whether effect modification varied across 
time, and all analyses were repeated separately for 6 months and 12 months, but these results 
are only discussed where they suggest different conclusions from the repeated measures 
analysis. RMM were also carried out separately for each level of the potential moderators to 
further illustrate any interaction effects.  
We decided to focus on the above approach (i.e., examining each moderator in a separate 
model) to aid the interpretation of the results. This approach does not account for the 
potential confounding effects of other effect modifiers, however, which might attenuate, or 
augment significant relationships (Friedman and Wall, 2005). Therefore, we also ran a single 
model including all putative moderator variables and their interaction terms.    
All RRM analyses used the xtmixed command in Stata version 11. RRM is a variance 
component model, with observations nested within subjects for the analysis of longitudinal 
data. Furthermore, RRM is consistent with the analyses conducted in the main trial paper. In 
order to maximise statistical power, we also examined the results of analyses that treated 
moderators as continuous variables where data were collected as such - age, baseline severity 
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(BDI-II), number of previous episodes and life events, whilst recognising that such analyses 
will be more difficult to interpret. 
Results 
Baseline characteristics 
The randomisation groups were similar in terms of the stratification and minimisation 
variables (baseline BDI-II score, whether participant’s general practice had a counsellor, 
prior treatment with antidepressants and duration of their current episode of depression 
(Wiles et al., 2013) and the other potential treatment moderators investigated (Table 1). 
Regarding the level of treatment-resistance to antidepressants, at randomisation 70% (327) 
had been prescribed their present antidepressants for more than 12 months, 80% (378) 
reported their current episode of depression as having lasted more than a year, and 80% (377) 
had been prescribed antidepressants previously to their current course of medication (Table 
1). 
It is important to understand if adherence to the intervention, and therefore treatment dose, 
varied by potential moderators as this could potentially explain any effect modification.  The 
level of adherence to the intervention (defined as the mean number of CBT sessions attended) 
were generally very similar across the levels of the potential moderators investigated, (Table 
1), suggesting that any observed effect modification was not due to differences in treatment 
adherence. However, there was some variation in education; the more highly educated 
attended the most sessions (mean 12.5, s.d. 5.9) and those without formal qualifications 
attended the least (mean 8.6, s.d. 6.5). There was also some variation in adherence by 
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longstanding physical illness, which is likely due to the low numbers of patients with any 
given illness.  
Main effects of potential moderators on outcome 
There was evidence of a main effect of age, regression coefficient = 0.11 (95% CI 0.02, 
0.20), p = 0.02, and baseline severity measured on the BDI-II (continuous), regression 
coefficient = 0.57 (95% CI 0.47, 0.67), p < 0.001, with weaker evidence on the CIS-R β = 
0.44 (95% CI -0.00, 0.88), p = 0.05. Older age and higher severity of depression indicated 
worse general outcome.  There was weak evidence for a main effect of longstanding illness (p 
= 0.08 from the Wald test), and little evidence of main effects of all other potential moderator 
variables (all p values ≥ 0.14).  
Effect modification by potential moderators 
The results obtained from the RMM suggested that age and to a lesser extent baseline BDI, 
were the only variables for which there was any evidence of an interaction between a 
potential moderator and the intervention. The interaction coefficients became more negative 
the higher the age category, suggesting that the higher the age category the greater the benefit 
of treatment (p-value for interaction effect = 0.012; Table 2). This was also consistent with 
the linear term, treatment × age, with a regression coefficient = -0.24 (95% CI -0.44, -0.04), p 
= 0.02, implying that age may modify the effectiveness of CBT, with older individuals 
gaining most treatment-derived benefit. It is worth noting however, that there is no 
suggestion of any material dis-benefit from CBT at any age.  
Regarding baseline severity, there was little evidence of effect modification in the 
dichotomous (severe/less severe) analysis of BDI-II scores or in the continuous analysis using 
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the CIS-R score. However, treating baseline BDI-II as a continuous variable we found weak 
evidence of modification, treatment × BDI interaction regression coefficient = 0.20 (95% CI 
0.00, 0.39), p = 0.05, indicating that CBT was less effective as baseline severity increased. 
However, including the treatment × BDI × time interaction in the RMM weakens the 
evidence for the severity interaction (p = 0.20), as does separate analysis of outcome at 6 
months (p = 0.22) and 12 months (p = 0.10), suggesting that the effect is not robust.  
When the RRM analyses were carried out separately at each level of the potential moderator 
variables the adjusted differences in mean BDI-II scores further demonstrated a lack of effect 
modification except for age, and baseline severity, as the differences in mean BDI-II scores 
between the levels of the potential moderators variables were similar, had overlapping 
confidence intervals and did not show any clear trends (Table 2). For the categorical age 
variable, however, the confidence intervals were overlapping but the coefficients were 
consistent with the earlier conclusion regarding this interaction that the older patients 
benefited most from CBT. Looking at the mean outcome scores (Supplementary Table 1) the 
younger subgroups of patients had better outcomes irrespective of treatment group, and thus 
had smaller treatment effects in terms of mean BDI score differences. The three-way 
treatment × moderator × time interactions suggested that there was little evidence that the 
relationships between any of the investigated potential moderators and the intervention varied 
over time (p’s ≥ 0.07). Analysing life events as continuous found no evidence for moderation 
(p = 0.58).  
The results from the full model combining all putative moderators and their interaction terms 
were broadly consistent with the results above (i.e., null), except that in the full model there 
was no evidence for effect modification by age or severity (all p’s > 0.12).  
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Discussion 
Summary of main findings 
This is the first study to examine moderators of response to CBT as a ‘next-step’ treatment 
for primary care patients whose depression had not responded to treatment with 
antidepressants. The level of non-response to antidepressants was high; the vast majority of 
our sample (70% -80%)  had been prescribed their present antidepressants for more than 12 
months, reported their current episode of depression as having lasted more than a year, and 
had been prescribed antidepressants previously to their current course. Of the fourteen 
variables assessed, age and to a lesser extent baseline BDI-II score, were the only variables 
with some statistical evidence for effect modification; older patients benefited the most from 
CBT, and there was weak evidence that the more severely depressed individuals benefited 
least. However, our results were not sufficiently precise to conclude either that CBT was, or 
was not, effective for the younger participants, and the moderation effect for baseline severity 
was not robust and was in the opposite direction to previous literature (Button et al., 2012). 
We found no evidence of effect modification by any other demographic variable, life events, 
longstanding illness/disability, personality trait, cognitive or psychological mindedness 
variables. We have previously shown that CBT as an adjunct to antidepressants produces 
better outcomes than antidepressants alone (Wiles et al., 2013). In the absence of strong 
evidence of moderation of this effect, we should assume that all patients who have not 
responded to antidepressants will benefit from referral for CBT.  
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Strengths and Limitations 
This is the first study to examine moderators of response to CBT in a difficult-to-treat 
sample, and the large sample (n = 469), and quality of the CoBalT trial data, is a major 
strength. However, the limitations associated with post-hoc subgroup analyses should be 
borne in mind when interpreting our findings (Brookes et al., 2001). Secondary subgroup 
analyses suffer from low statistical power, but they are also prone to false positive findings 
due to multiple testing. To retain power in this exploratory analysis we did not control for 
multiple comparisons. Caution is therefore required when interpreting findings for a single 
study. Consistent findings across studies are required before we can consider moderators as 
clinically informative and, ideally, meta-analyses of randomised studies should be conducted 
using individual patient data to achieve sufficient statistical power. Although our sample size 
(n =469) is one of the largest clinical trials of CBT to date, it is small for testing interactions, 
creating uncertainty about the reliability of the estimates. Multiple testing increases the 
likelihood of chance findings. However, we tested fourteen different variables and only found 
evidence for one moderator. The variables we report here are the only variables we have 
examined for moderation.  
Number of CBT sessions attended is a relatively crude measure of treatment received, as 
other factors such as therapist competence, fidelity to the CBT model and use of “active” 
techniques have been associated with effectiveness in other disorders (Freeman et al., 2013; 
Norrie et al., 2013).  However, our aim is to identify moderators that predict response in a 
pragmatic sense and we use number of sessions to, albeit crudely, describe adherence by 
moderator. CBT often focuses on interpersonal factors or relationship issues that might be 
differentially important for someone who is married, or in a stable relationship, than for 
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someone who is single. It is unclear how individuals in a stable relationship were captured by 
marital status in this study as they may have self-identified as “single” or “living as married”.   
Finally, we cannot eliminate the possibility that there are other moderating factors, including 
those related to previous treatment, which we have not measured or studied in this research. 
Comparison of findings with previous literature     
We found evidence for effect modification by age, with older patients benefiting the most 
from CBT. There is no precedent for age as a moderator (Button et al., 2012; Fournier et al., 
2009) so we treat our result with caution, as it may be an artefact of multiple testing. In 
contrast to RCTs of previously untreated episodes of depression, the mean age of patients in 
CoBalT was higher, with over half the sample being 50 years or older when they entered the 
study (Wiles et al., 2013). We would not expect this in itself to influence the findings in terms 
of the pattern of coefficients, especially given the good balance between the trial arms with 
respect to age. Yet it may have increased our power to detect this particular interaction 
compared with other studies with a younger age distribution. Alternatively, it may reflect 
something specific to the treatment resistant population. CBT was most effective for patients 
over 40 years, and least effective in patients aged 30 to 39 years. All patients improved apart 
from those in the older subgroups who were in the usual care arm (and therefore did not have 
the option to receive CBT). This lack of improvement in the usual care arm explains the 
greater treatment effect observed in the older subgroups, while the younger subgroups had 
better outcomes irrespective of treatment. It is also worth noting that given the small numbers 
(n = 61) in the 30 to 39 subgroup, the confidence intervals around the estimate are wide, 
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providing no evidence for either treatment benefit or harm. Further research is required to 
assess whether this finding is robust, and explore potential mechanisms.    
In contrast with previous research (Button et al., 2012; Fournier et al., 2009; Sotsky et al., 
1991), we did not identify marital status or stressful life events as moderators in the present 
sample. The point estimates for marital status were consistent with single individuals gaining 
least from CBT, but there was no statistical evidence for effect modification. Number of 
recent stressful life events has been identified as a potential moderator in two previous studies 
(Button et al., 2012; Fournier et al., 2009). We previously found individuals with 3 or more 
recent life events gained the least from CBT compared to waiting list control, where around 
half of individuals in both arms were prescribed antidepressants. In contrast, Fournier and 
colleagues found individuals with more stressful life events gained most benefit from CBT 
but this was in direct comparison with antidepressant medication The estimates for life events 
in this study offers little support to either of the previous findings (Button et al., 2012; 
Fournier et al., 2009), which taken together suggest that number of recent life events is not a 
reliable moderator of response to CBT, at least in this population that is concurrently taking 
antidepressant medication. However, research suggests that life events become less important 
in the aetiology of depression with increased recurrence (Lewinsohn et al., 1999), so it may 
be inappropriate to generalise the findings from the chronic population in CoBaLT to other 
trials of CBT for depression.  
Previous studies suggest pre-treatment severity of depression is the most reliable moderator 
of response to CBT, with the more severely depressed benefiting most (Button et al., 2012; 
Driessen et al., 2010). However, meta-analytic findings that rely on aggregate data (Cuijpers 
et al., 2008) and issues of scaling confuse these severity findings, which may be an artefact of 
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assessing outcomes using continuous measures. For example, a 5-point reduction in scores 
for someone whose baseline was 50 is a proportionally smaller improvement than is a 5-point 
change from a baseline of 15. We found weak evidence of an interaction with baseline 
severity as measured on continuous BDI-II, but not in the categorical or CIS-R analyses, 
which suggests that the interaction is not robust. Moreover, this effect was in the opposite 
direction to that predicted by the previous literature so we also treat this result with caution. 
This may reflect the nature of our treatment resistant sample; in CoBalT, patients were 
selected for their non-response to antidepressants. In our previous study (Button et al., 2012), 
less severe depressions, as assessed by symptoms, improved equally well irrespective of 
receiving CBT or waiting list control; in contrast, CBT was particularly effective for severe 
depression, which did not improve in the waiting list arm. The participants in CoBalT had a 
poorer outcome than in our previous study as we selected patients through the resistance of 
their symptoms to pharmacotherapy. This may explain the different pattern of effect 
modification by severity of symptoms in this group. It is of note, however, that baseline 
symptom severity in CoBalT was similar to other RCTs of depression in the UK (Chalder et 
al., 2012; Kessler et al., 2009; Lewis et al., 2011; Wiles et al., 2012). The CoBalT sample was 
nevertheless more “severe” in terms of chronicity, number of previous episodes, 
comorbidities and non-response to medication (Wiles et al., 2013). This suggests that to 
capture the extent of illness that we see clinically, we need to account for both severity and 
chronicity, especially in those whose symptoms are resistant to antidepressants.  
Assessing individuals’ suitability for therapy is an important part of clinical practice, which 
often focuses on interpersonal factors, personality, and psychological mindedness (Safran, 
1990). However, the literature on this area is based more on clinical opinion (Safran, 1990) 
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than empirical evidence. Consistent with previous research assessing personality traits in 
untreated episodes of depression (Fournier et al., 2009; Spek et al., 2008), we found no 
evidence that neuroticism was a moderator of response to CBT in treatment resistant 
individuals. Patients with lower dysfunctional attitudes have been found to do better in 
treatment arms (CBT and antidepressants) relative to a placebo tablet (Sotsky et al., 1991), 
whereas individuals with high dysfunctional attitudes have been found to do better on 
medication that psychotherapy (Shankman et al., 2013). However, other studies found no 
evidence for effect modification by dysfunctional attitudes (Fournier et al., 2009; Jacobs et 
al., 2009). In our sample, neither dysfunctional attitudes nor meta-cognitive awareness were 
associated with differential response. Therefore, the practice of selecting patients for CBT 
based on assessments of personality and psychological mindedness remains empirically 
unsupported. Indeed, such practice may put in place unprecedented barriers to individuals 
receiving CBT and may contribute to the perceived inequalities in psychotherapy provision 
(Jokela et al., 2013). 
Clinical implications 
Combined CBT and pharmacotherapy are more effective than either treatment alone 
(Cuijpers, 2014; Cuijpers et al., 2009a). However, antidepressants are often prescribed as the 
first-line treatment for adults with moderate to severe depression, with anecdotal evidence 
suggesting that, in practice, CBT is often reserved for those patients where medication has 
failed. CBT as an adjunct to pharmacotherapy is an effective ‘next step’ treatment for patients 
whose depression has not responded to treatment with antidepressants (Wiles et al., 2013). 
However, to further improve patients outcomes by tailoring treatment in line with stratified 
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medicine (Hingorani et al., 2013), it is helpful understand if there are any factors associated 
with differential treatment response in this difficult to treat group. We found that response to 
CBT differed with age, with little evidence that patients under 39 years of age were 
benefitting from treatment. However, these younger patients had a better outcome and lower 
depression scores at the end of the trial than the older participants.  Given the small numbers 
of patients and wide confidence intervals in this subgroup, we caution against using age to 
inform treatment decisions until further research replicates this effect.  We have found no 
evidence to suggest that non-response varied systematically with other patient characteristics. 
Therefore, we suggest that CBT be offered to all individuals whose depression has not 
responded to treatment with antidepressant medication.   
 
Research implications 
The aims of stratified medicine are laudable and identifying moderators is useful if pursuing 
stratified models of care. However, as our findings indicate, there is little reliable evidence of 
differential response from the relatively comprehensive set of moderators that has been 
examined in the literature to date. One reason for this might be the lack of understanding of 
the mechanisms of action by which various treatments work. Studies that examine mediators 
of treatment response may be useful in this regard and may provide a more detailed 
understanding of why a treatments works. This in turn may inform modifications to 
interventions in order to improve effectiveness for a broad range of patients. 
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Conclusions 
The evidence to date does not support a stratified approach to prescribing CBT in depressed 
patients who have not responded to antidepressants, and we suggest therefore that CBT is 
offered to all patients in this group. There are potential benefits of stratified medicine for 
patients, and further research into moderators of response to CBT is required. Convincing 
evidence of moderators of response to CBT may require much larger studies with 
confirmatory findings and this may need individual patient data meta-analyses. However, it is 
worth questioning the clinical utility of identifying effect modifiers if the size of treatment 
effect modification is so small that obtaining reliable evidence requires huge studies. In the 
light of this, our results suggest that CBT should be offered to all those who have not 
responded to antidepressant medication.  
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Table 1. Comparison of baseline characteristics between randomisation groups, and 
adherence to CBT intervention by putative moderator variables  
Characteristic Usual care Intervention 
Number of CBT 
sessions attended 
  (n=235) (n=234) mean (SD) 
Demographic and life factors:    
Centre: n (%)    
Bristol  95 (40.4%) 95 (40.6%)  
Exeter 82 (34.9%) 79 (33.8%)  
Glasgow 58 (24.7%) 60 (25.6%)  
     
GP practice has a counsellor: n (%) 116 (49.4%) 112 (47.9%)  
    
Female: n (%) 178 (75.7%) 161 (68.8%)  
     
Age (continuous): mean (SD) 50 yrs (11.5) 49.2 yrs (11.9)  
     
Age (categories): n (%)    
<30 11 (4.7%) 20 (8.6%) 11.0 (6.4) 
30-39 32 (13.6%) 29 (12.4%) 10.7 (6.6) 
40-49 69 (29.4%) 64 (27.4%) 11.0 (6.3) 
>49 123 (52.3%) 121 (51.7%) 11.6 (6.2) 
     
Highest level of education: n %    
A Level/Higher Grade or abovea 105 (45.5%) 112 (48.3%) 12.5 (5.9) 
Other Qualifications - GCSE or equivalent 67 (29.0%) 63 (27.2%) 11.5 (5.9) 
No formal qualifications 59 (25.5%) 57 (24.6%) 8.6 (6.5) 
     
Marital status: n (%)    
Single 45 (19.2%) 44 (18.8%) 9.9 (6.6) 
Married/living as married 128 (54.5%) 120 (51.3%) 11.6 (6.4) 
Separated/divorced/widowed 62 (26.4%) 70 (29.9%) 11.5 (5.8) 
     
Life events in the past 6 months: n (%)    
0 events 71 (30.2%) 62 (26.5%) 11.0 (6.2) 
1-2 events 135 (57.5%) 138 (59.0%) 11.5 (6.2) 
≥3 events 29 (12.3%) 34 (14.5%) 10.7 (6.8) 
     
Illness characteristics:    
BDI-II score: mean (SD) 31.8 (10.5) 31.8 (10.9)  
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BDI-II severity group: n (%)    
Less severe 103 (43.8%) 102 (43.6%) 10.8 (6.0) 
Severe 132 (56.2%) 132 (56.4%) 11.6 (6.4) 
     
CIS-R depression severity score: mean (SD)*# 14.9 (2.9) 14.8 (3.1) Low 11.1 (6.0) 
    High 11.3 (6.5) 
Number of prior episodes of depression: n %    
0-1 episodes 45 (19.2%) 46 (19.7%) 10.5 (6.4) 
2-4 episodes 61 (26.0%) 72 (30.8%) 10.7 (6.4) 
≥5 episodes 129 (54.9% 116 (49.6%) 11.9 (6.1) 
     
Duration of current episode of depression: n 
(%)   
 
<1year 52 (22.1%) 58 (24.8%) 10.2 (6.6) 
1-2 years 43 (18.3%) 40 (17.1%) 12.0 (6.1) 
>2 years 140 (59.6%) 136 (58.1%) 11.5 (6.1) 
     
Previously prescribed antidepressants: n (%) 190 (80.9%) 187 (79.9%)  
     
Anxiety score: mean (SD) 2.4 (1.5) 2.5 (1.5)  
     
Post Traumatic Stress Disorder score: mean 
(SD)* 2.1 (1.5) 2.0 (1.5) Low 10.7 (6.5) 
    High 11.6 (6.0) 
    
Long-standing illnesses: n (%)    
No chronic illness 54 (23.0%) 64 (27.4%) 10.8 (6.3) 
Diabetes 6 (2.6%) 10 (4.3%) 7.8 (7.2) 
Asthma 17 (7.2%) 11 (4.7%) 11.5 (5.6) 
Arthritis 19 (8.1)% 19 (8.1%) 10.7 (7.6) 
Heart disease 4 (1.7%) 5 (2.1%) 16.0 (2.9) 
High blood pressure 16 (6.8%) 11 (4.7%) 12.4 (4.1) 
Lung disease 4 (1.7%) 1 (0.4%) 4.0 (NA) 
More than one of the above 44 (18.7%) 35 (15%) 10.7 (6.4) 
None of the above but other 71 (30.2%) 78 (33.3) 12.0 (6.0) 
     
Personality, cognition and psychological 
mindedness:   
 
Dysfunctional attitudes score: mean (SD)* 36.9 (10.6) 35.8 (11.0) Low 10.4 (6.5) 
    High 12.1 (5.9) 
    
Meta-cognitive awareness score: mean (SD)* 37.4 (7.6) 37.5 (7.7) Low 11.7 (6.2) 
    High 10.8 (6.3) 
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Neuroticsm score: mean (SD)* 4.1 (0.6) 4.0 (0.7) Low 10.4 (6.5) 
   High 12.0 (5.9) 
 
aA-levels are UK national qualifications generally taken at age 18 years, and qualifications at this 
level or equivalent are usually required for entry to university/higher education 
* Continuous variables were median split to produce Low and High categories 
# Low and High categories defined as a score of less than 2 and 2 or more respectively 
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Table 2. Treatment effect (b) averaged over both follow-up times for each level of potential 
moderator from random effect regression models (RRM) after adjustment for design 
variables.    
Moderator n ba 95% CI pb 
Demographic and life factors:     
Age    0.012 
<30 32 -2.4 (-8.1, 3.3)  
30-39 50 -0.5 (-7.0, 6.0)  
40-49 112 -5.0 (-8.9, -1.1)  
>49 209 -6.6 (-9.4, -3.9)  
      
Highest level of education    0.43 
A Level/Higher Grade or above 198 -4.6 (-7.5, -1.7)  
Other Qualifications - GCSE or equivalent 118 -3.3 (-7.7, 1.1)  
No formal qualifications 85 -7.5 (-12.0, -3.0)  
      
Marital status    0.39 
Single 67 -2.5 (-7.3, 2.4)  
Married/living as married 213 -6.1 (-8.8, -3.3)  
Separated/divorced/widowed 123 -5.0 (-9.2, -0.7)  
      
Life events in the past 6 months    0.93 
0 events 108 -5.0 (-9.0, -1.0)  
1-2 events 236 -5.7 (-8.4, -3.1)  
≥3 events 59 -6.9 (-12.2, -1.5)  
      
Illness characteristics:     
Baseline BDI-II severity    0.56 
Less severe 174 -5.8 (-8.1, -3.5)  
Severe 229 -4.6 (-7.8, -1.3)  
      
Baseline CIS-R depression severity*    0.91 
Low 177 -5.4 (-8.0, -2.8)  
High 226 -5.1 (-8.2, -2.0)  
      
Number of prior episodes of depression    0.93 
0-1 episodes 73 -5.2 (-10.2, -0.2)  
2-4 episodes 126 -5.5 (-9.1, -1.9)  
≥5 episodes 204 -4.7 (-7.7, -1.7)  
      
Duration of current episode of depression    0.72 
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<1year 101 -6.1 (-10.2, -2.0)  
1-2 years 68 -3.5 (-8.4, 1.4)  
>2 years 234 -5.2 (-7.9, -2.5)  
      
Anxiety score#    0.82 
Low 121 -4.6 (-7.9, -1.3)  
High 282 -5.3 (-7.9, -2.8)  
      
Post Traumatic Stress Disorder score*    0.36 
Low 161 -3.5 (-6.6, -0.5)  
High 242 -5.9 (-8.7, -3.2)  
      
Illnesses    0.20 
No chronic illness 168 -2.4 (-6.8, 2.0)  
Diabetes 17 1.5 (-8.9, 11.9)  
Asthma 19 -8.4 (-18.5, 1.7)  
Arthritis 29 -1.3 (-8.7, 6.1)  
Heart disease 10 -15.4 (-34.5, 3.7)  
High blood pressure 19 -10.1 (-22.8, 2.5)  
Lung disease 2 0 omitted  
More than one of the above 61 -9.6 (-15.0, -4.2)  
None of the above but other 139 -4.9 (-8.2, -1.6)  
      
Personality, cognition and psychological 
mindedness:     
Dysfunctional attitudes score*    0.46 
Low 189 -5.6 (-8.4, -2.8)  
High 214 -4.7 (-7.7, -1.7)  
      
Meta-cognitive awareness score*    0.23 
Low 183 -8.2 (-11.5, -4.8)  
High 220 -3.0 (-5.7, -0.3)  
      
Neuroticism score*    0.39 
Low 194 -3.3 (-6.2, -0.4)  
High 209 -6.4 (-9.4, -3.3)  
 
a Values represent treatment effects, that is differences in mean BDI-II scores between 
randomisation groups, as estimated from random effect regression models carried out at each 
level of moderator with the repeated measure of follow-up time and adjustment for design 
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variables. Negative values represent more desirable outcomes (i.e. Greater treatment-derived 
benefit). Continuous variables were median split to produce Low and High levels.  
b P values for formal test of treatment effect modification  for each moderator from random 
effect regression model testing moderator x treatment interaction with the repeated measure 
of follow-up time and adjustment for design variables and the moderator x treatment x time 
interaction. Treatment effects varied little over time (P’s > 0.07). Where there are three or 
more subgroups, p values are based on Wald tests. Continuous variables were treated as 
continuous.    
# Low and High categories defined as a score of less than 2 and 2 or more respectively.  
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Supplementary Table 1. Adjusted differences in mean BDI-II score between randomisation groups to illustrate further any interaction effects 
Moderator Baseline 6 months   12 months  
  Intervention  Usual care  Intervention  Usual care  Intervention  Usual care 
  n Mean  n Mean  n Mean  n Mean  n Mean  n Mean 
Demographic and life factors:                  
Age                  
<30 20 31.7  11 35.4  17 19.2  11 20.2  15 15.4  10 15.3 
30-39 29 33.7  32 32.6  26 20.8  28 22.2  24 17.8  24 16.0 
40-49 64 33.1  69 33.5  57 20.7  61 27.1  55 18.1  56 22.5 
>49 121 30.6  123 30.4  106 17.5  113 24.1  103 16.5  108 23.1 
                   
Highest level of education                  
A Level/Higher Grade or above 112 31.0  105 31.0  101 18.8  93 23.0  97 15.8  93 20.7 
Other Qualifications - GCSE or 
equivalent 63 32.2  67 31.2  60 19.7  63 23.6  58 17.5  56 19.8 
No formal qualifications 57 33.1  59 34.5  44 18.6  53 28.7  41 19.6  45 25.3 
                   
Marital status                  
Single 44 33.5  45 31.6  35 22.9  40 24.5  32 19.5  39 19.4 
Married/living as married 120 32.4  128 31.3  109 18.7  114 23.5  104 16.2  109 22.4 
Separated/divorced/widowed 70 29.5  62 33.2  62 17.1  59 26.5  61 17.2  50 21.8 
                   
Life events in the past 6 months                  
0 events 62 29.4  71 31.4  55 16.3  64 21.7  53 15.8  61 20.7 
1-2 events 138 32.4  135 31.4  120 19.7  121 24.9  116 17.6  113 22.1 
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≥3 events 34 33.6  29 35.0  31 20.7  28 29.1  28 17.1  24 22.3 
                   
Illness characteristics:                  
Baseline BDI-II severity                  
Less severe 102 22.5  103 22.1  88 12.4  97 18.8  86 11.9  93 16.5 
Severe 132 38.9  132 39.4  118 23.8  116 29.3  111 21.0  105 26.2 
                   
Baseline CIS-R depression severity*                  
Low 102 25.3  101 25.3  90 14.6  96 19.4  87 12.3  89 17.6 
High 132 36.8  134 36.7  116 22.3  117 28.7  110 20.8  109 25.0 
                   
Number of prior episodes of 
depression                  
0-1 episodes 46 32.5  45 30.0  38 20.2  40 24.5  35 17.1  39 22.6 
2-4 episodes 72 29.7  61 27.8  64 18.8  59 22.4  62 14.8  53 19.9 
≥5 episodes 116 32.7  129 34.4  104 18.5  114 25.6  100 18.4  106 22.2 
                   
Duration of current episode of 
depression                  
<1year 58 29.2  51 28.4  51 16.8  48 21.9  50 12.8  45 18.7 
1-2 years 40 30.5  43 31.1  35 20.5  39 23.5  33 16.4  38 21.6 
>2 years 136 33.2  140 33.3  120 19.4  126 25.8  114 19.1  115 22.8 
                   
Anxiety score#                  
Low 67 26.1  65 26.8  60 16.0  60 20.8  61 15.2  57 20.2 
High 167 34.0  170 33.8  146 20.1  153 26.0  136 17.9  141 22.3 
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Post Traumatic Stress Disorder 
score*                  
Low 93 28.4  87 28.2  81 16  81 21.2  80 16.5  77 17.9 
High 141 34.0  148 34.0  125 20.8  132 26.5  117 17.4  121 24.0 
                   
Longstanding illnesses                  
No chronic illness 64 28.5  54 31.8  55 18.2  48 20.9  52 14.8  45 18.9 
Diabetes 10 30.9  6 35.8  10 27.7  6 29.8  7 20.4  6 28.3 
Asthma 11 35.3  17 32.6  9 13.2  13 21.0  10 17.3  13 22.3 
Arthritis 19 27.1  19 28.9  15 20.2  17 22.2  14 18.7  16 23.5 
Heart disease 5 40.8  4 40.5  5 29.4  4 35.5  5 25.6  3 25.7 
High blood pressure 11 36.2  16 29.7  9 11.8  15 25.7  10 14.0  13 27.3 
Lung disease 1 16.0  4 30.8  1 6.0  4 21.3  1 9.0  4 21.8 
More than one of the above 35 36.7  44 32.8  31 20.9  41 28.8  30 20.2  38 25.8 
None of the above but other 78 32.0  71 31.5  71 18.3  65 24.5  68 16.5  60 18.4 
                   
Personality, cognition and 
psychological mindedness:                  
Dysfunctional attitudes score*                  
Low 115 29.2  111 28.4  97 18.0  99 22.7  92 15.9  94 21.4 
High 119 34.2  124 34.9  109 19.8  114 26.1  105 18.0  104 21.9 
                   
Meta-cognitive awareness score*                  
Low 104 33.0  105 34.2  96 18.2  92 26.2  87 15.7  84 24.0 
High 130 30.7  130 29.9  110 19.6  121 23.2  110 18.0  114 19.9 
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Neuroticism score*                  
Low 115 28.6  102 27.8  99 17.8  93 21.0  95 15.7  89 19.9 
High 119 34.8  133 34.9  107 20.0  120 27.6  102 18.3  109 23.1 
 
 
* Continuous variables were median split to produce Low and High categories. 
# Low and High categories defined as a score of less than 2 and 2 or more respectively.
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